EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mesenchymal Stromal Cell-Based Immunotherapy for Type 1 Diabetes: From Bench to Bedside

Alexey Lupatov, Irina Pokusaeva iD, Irina Kholodenko iD, Marina Shestakova iD, Kirill Larin, Rita Khusainova iD, Ildar Minniakhmetov iD, Vladimir Chekhonin iD, Konstantin Yarygin iD, Natalia Mokrysheva

International Journal of Molecular Sciences · 08.11.2026 · 27 (21) · 10005

DOI: 10.3390/ijms272110005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.11.2026. Verfasst von Alexey Lupatov und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Chemistry (IBMC), 119121 Moscow, Russia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Mesenchymal Stem Cells, Mesenchymal Stem Cell Transplantation, Immunotherapy. Die Arbeit nennt 239 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of the Russian Federation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 1 diabetes mellitus (T1D) is an autoimmune disease characterized by the progressive destruction of pancreatic β-cells. Despite advances in glucose monitoring and insulin delivery, current treatments do not directly target the underlying autoimmune process. The administration of mesenchymal stromal cells (MSCs) represents a promising therapeutic approach due to their immunomodulatory, anti-inflammatory, and regenerative properties. Unlike therapies targeting individual immune pathways, MSCs exert broad immunomodulatory effects. This review integrates current knowledge of T1D immunopathogenesis with evidence on MSC-mediated immunomodulation, highlighting the ability of MSCs to modulate multiple interconnected mechanisms, including innate and adaptive immunity, antigen presentation, inflammatory signaling, and immune tolerance. Preclinical evidence suggests that MSCs may attenuate inflammation, regulate immune responses, preserve β-cell function, and improve metabolic outcomes. A preliminary but encouraging finding from clinical studies is that MSC administration may produce sustained beneficial effects after a limited number of injections. However, this observation remains tentative and requires confirmation in further studies. Standardized treatment protocols, adequately powered controlled trials, and long-term follow-up are needed to establish the clinical efficacy, durability of response, and optimal use of MSC-based therapy in T1D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationImmunotherapyHumansAnimalsImmunomodulationInsulin-Secreting Cells

Stichwörter der Autor:innen

autoimmunitycell-based therapyimmunomodulationmesenchymal stromal cellstype 1 diabetes mellitus

Autor:innen und Institutionen

  • Institute of Biomedical Chemistry (IBMC), 119121 Moscow, Russia.
  • Endocrinology Research Centre, 117292 Moscow, Russia.

ORCID-Profile: Irina Pokusaeva, Irina Kholodenko, Marina Shestakova, Rita Khusainova, Ildar Minniakhmetov, Vladimir Chekhonin, Konstantin Yarygin

Förderung

  • Ministry of Science and Higher Education of the Russian Federation

Zitieren

APA

Lupatov, A., Pokusaeva, I., Kholodenko, I., Shestakova, M., Larin, K., Khusainova, R., Minniakhmetov, I., Chekhonin, V., Yarygin, K., & Mokrysheva, N. (2026). Mesenchymal Stromal Cell-Based Immunotherapy for Type 1 Diabetes: From Bench to Bedside. International Journal of Molecular Sciences, 27(21), 10005. https://doi.org/10.3390/ijms272110005

Vancouver

Lupatov A, Pokusaeva I, Kholodenko I, Shestakova M, Larin K, Khusainova R, et al. Mesenchymal Stromal Cell-Based Immunotherapy for Type 1 Diabetes: From Bench to Bedside. International Journal of Molecular Sciences. 2026;27(21):10005. doi:10.3390/ijms272110005

BibTeX
@article{Lupatov2026,
  author = {Lupatov, Alexey and Pokusaeva, Irina and Kholodenko, Irina and Shestakova, Marina and Larin, Kirill and Khusainova, Rita and Minniakhmetov, Ildar and Chekhonin, Vladimir and Yarygin, Konstantin and Mokrysheva, Natalia},
  title = {Mesenchymal Stromal Cell-Based Immunotherapy for Type 1 Diabetes: From Bench to Bedside},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {21},
  pages = {10005},
  doi = {10.3390/ijms272110005}
}
Kostenlos starten →